Synopsis: Temozolomide is the first oral effective imidazo tetrazine antitumor drug. It belongs to the second generation alkylating agent with antitumor activity. It does not need intrahepatic metabolic activation after oral administration. It is characterized by easy penetration through the blood-brain barrier, good tolerance and no superimposed toxicity with other drugs. It has synergistic effect with radiotherapy. It is suitable for malignant gliomas that relapse after routine treatment, For example, glioblastoma multiforme or degenerative astrocytoma is also the first-line drug for the treatment of metastatic melanoma.
Structural formula:
Properties
Summary
Temozolomide is the first oral effective imidazo tetrazine antitumor drug. It belongs to the second generation alkylating agent with antitumor activity. It does not need intrahepatic metabolic activation after oral administration. It is characterized by easy penetration through the blood-brain barrier, good tolerance and no superimposed toxicity with other drugs. It has synergistic effect with radiotherapy. It is suitable for malignant gliomas that relapse after routine treatment, For example, glioblastoma multiforme or degenerative astrocytoma is also the first-line drug for the treatment of metastatic melanoma.
Manufacturing
